Save 20% on Press Releases and More with NNW Prime! Click to View Details

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Highlights Expanding Opportunities in GLP-1 Drug Market and Strategic Focus on DehydraTECH Integration

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) provided a strategic update on its efforts to leverage its DehydraTECH technology within the rapidly growing GLP-1 drug market, projected to surpass $100 billion annually. GLP-1 drugs, initially approved for diabetes and weight loss, are now being explored for broader applications, including cardiovascular, liver, and kidney diseases, as well as … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Highlights Expanding Opportunities in GLP-1 Drug Market and Strategic Focus on DehydraTECH Integration”

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Friday that it had received approval from an independent review board for its planned human pilot study #3. The approval signals that the company can begin the study, which aims to investigate the first ever DehydraTECH-processed version of tirzepatide, a dual action … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide”

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, looks to offer a better alternative to diabetes management and treatment through its patented DehydraTECH(TM) technology. “Lexaria has recently made strides with glucagon-like peptide-1 (‘GLP-1’) studies. It has reported positive interim results from an animal study on diabetes. This milestone best showcases the … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs”

Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations

Lexaria (NASDAQ: LEXX), a global innovator in drug delivery platforms, has, since 2016, worked on the development of its patented DehydraTECH(TM) technology. It has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. These efforts have earned it 46 patents in … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations”

Lexaria Bioscience Corp. (NASDAQ: LEXX) Demonstrates Continued DehydraTECH(TM)-Liraglutide Performance with Ongoing GLP-1 Diabetes Animal Study

Lexaria (NASDAQ: LEXX), a global innovator in drug delivery platforms, is reporting on its eight-week body weight results from its WEIGHT-A24-1 ongoing animal study. This study explores Lexaria’s patented technology, DehydraTECH(TM), and its potential in addressing diabetes and weight loss. More importantly, it looks to establish whether DehdyraTECH processing results in higher brain absorption than … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Demonstrates Continued DehydraTECH(TM)-Liraglutide Performance with Ongoing GLP-1 Diabetes Animal Study”

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently released its fiscal report for the third quarter of the 2024 financial year (“Q3, 2024”). “Of note was growth in cash and marketable securities from $1.5 million during the same period in the 2023 financial year to $8.5 million as of May 31, 2024. The company reduced certain R&D … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program”

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, provided a strategic letter from outgoing CEO Chris Bunka updating all stakeholders. In the strategic update, Bunka discussed Lexaria’s performance in the capital markets; the company’s Phase 1b DehydraTECH-CBD hypertension trial and Australian-registered Phase 1b DehydraTECH-GLP-1 diabetes and weight-loss study; ongoing R&D; and … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO”

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the appointment of Richard Christopher as the new CEO, effective August 31, 2024. Mr. Christopher is a recognized industry veteran with over three decades of experience in the medical device and pharmaceutical industries. He has domestic and international experience in leadership, … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO”

Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) Liraglutide in Ongoing Diabetes Animal Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its 4-week and 8-week blood glucose results from its WEIGHT-A24-1 animal study (the “study”). This study will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination . The ongoing study uses diabetic, pre-conditioned Zucker … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) Liraglutide in Ongoing Diabetes Animal Study”

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Material Transfer Agreement to Evaluate DehydraTECH(TM) Technology in Pre-Clinical Setting

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has entered into a Materials Transfer Agreement with a pharmaceutical company. Under the terms of the agreement, the pharmaceutical company will evaluate Lexaria’s DehydraTECH(TM) technology in a pre-clinical setting. Lexaria will be responsible for formulating and supplying certain DehydraTECH compositions, with the pharmaceutical … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Material Transfer Agreement to Evaluate DehydraTECH(TM) Technology in Pre-Clinical Setting”

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000